Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

Income Statement

Follow revenue through to earnings.

Revenue

$12.14M

FY 2025 · Annual

+73.4% YoY

Operating Income

-$104.57M

FY 2025 · Annual

Net Income

-$99.50M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007M12.14M
Cost of Revenue00001.71M
Gross Profit0007M10.43M
Gross Margin———100.0%85.9%
Research & Development86.78M92.89M103.39M118M94.3M
Selling, General & Admin26.96M30.65M28.88M28.72M22.41M
Operating Expenses113.74M123.54M132.28M146.71M115M
Depreciation & Amortization915K1.32M1.17M1.77M1.71M
EBITDA(110.78M)(114.11M)(120.66M)(125.4M)(97.79M)
EBITDA Margin———-1791.4%-805.5%
Operating Income(113.74M)(123.54M)(132.28M)(139.71M)(104.57M)
Operating Margin———-1995.9%-861.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses2.04M8.1M10.44M12.54M5.07M
Income Before Tax(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Pre-Tax Margin———-1816.8%-819.6%
Income Tax Expense00000
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Net Margin———-1816.8%-819.6%
EPS (Basic)(2.33)(2.27)(2.02)(1.68)(1.29)
EPS (Diluted)(2.33)(2.27)(2.02)(1.68)(1.29)
Weighted Avg Shares47.6M47.37M60.36M75.81M76.96M
Weighted Avg Shares (Diluted)47.6M47.37M60.36M75.81M76.96M

PRLD Earnings Waterfall · TTM

NASDAQ:PRLD · Revenue to Net Income

Key Ratios

EPS$-1.06
Gross Margin72.9%
Net Margin-205.5%
P/E Ratio-2.9
P/S Ratio27.7

Analysis

$16.7M of revenue converted into -$77.8M of net income for the selected period. Gross margin is 72.9% and net margin is -205.5%, showing how much revenue survives after costs and taxes. EPS is $-1.06, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportSep 10, 2026
10-QQuarterly reportAug 11, 2026
8-KCurrent reportAug 11, 2026
SC 13GSC 13G filingJul 8, 2026
8-KCurrent reportJun 10, 2026

How much revenue does PRLD generate?

Prelude Therapeutics Incorporated (PRLD) reported $12.14M of revenue in fiscal 2025.

Is PRLD profitable?

Prelude Therapeutics Incorporated (PRLD) reported -$99.50M of net income, with a net margin of -819.6%.